放射性核素骨显像联合血清CA15-3、CA50、IL-8评价乳腺癌骨转移的临床意义

Assessment of bone metastasis of breast cancer by radionuclide bone scan combined with CA15-3,CA50 and IL-8 on

目的评价血清CA15-3、CA50、IL-8联合放射性核素骨显像对乳腺癌患者骨转移诊断的临床意义。方法利用SPECT/CT对乳腺癌患者进行骨骼放射性核素骨显像,应用化学发光法和放射免疫法对84例乳腺癌患者(均为女性)进行血清CA15-3、CA50、IL-8含量检测,并与34名正常人(均为女性)进行相关对比分析。结果乳腺癌患者骨转移的血清CA15-3、CA50、IL-8含量水平明显高于正常人组(P<0.01),乳腺癌骨转移组灶数>2个的肿瘤标志物水平明显高于灶数≤2个的肿瘤标志物水平(P<0.01)。结论在进行放射性SPECT/CT显像同时,进行血清CA15-3、CA50和IL-8的检测,能够尽早发现乳腺癌骨转移。

Objective To assess the value of radionuclide bone scan combined with serum CA15-3,CA50,11.8 in the diagnosis of bone metastasis of breast cancer. Methods Patients with breast cancer were tested by SPECT/CT for bone scanning, and serum CA15-3,CA50, IL-8 of 84 breast cancer patients （females） were detected by RIA and CLIA. Then,all relative data of the breast cancer patients were compared with those of 34 healthy people （females）. Results The serum CA15-3,CAS0, IL-8 levels in breast cancer patients with bone metastasis were significantly high- er than those in the healthy people（ P 〈0.01）. Among all the breast cancer patients, the tumor marker levels in pa- tients with more than 2 bone lesions were significantly higher than those in patients with 2 or less than 2 bone lesions （ P 〈0.01 ）. Conclusion Testing serum CA15-3,CAS0,IL-8 levels while taking SPECT/CT can help discover bone metastasis breast cancer early.